Wedbush Issues Pessimistic Estimate for RVMD Earnings
Wedbush analysts have lowered their 2029 earnings projection for Revolution Medicines, Inc. (NASDAQ: RVMD) from $1.47 to $1.23 per share. The updated report signals a more reserved stance on the biotech firm’s long-term performance outlook.
20 hours ago
1 min read
